Pharmacokinetics of Granulated Compound Containing Meloxicam in Broilers

The global restriction of antimicrobial growth promoters has intensified the search for alternative strategies to sustain poultry health and productivity. One proposed mechanism underlying the historical efficacy of antibiotic performance enhancers is the modulation of intestinal inflammation. In this context, meloxicam (MLX), a preferential COX-2 inhibitor and non-steroidal anti-inflammatory drug, has emerged as a potential candidate for investigation. However, pharmacokinetic data in broiler chickens remain limited, particularly for practical oral formulations intended for production systems. This study aimed to characterize the pharmacokinetic profile of a novel granulated MLX formulation in male Cobb 500 broiler chickens following single-dose administration. Seventy-two 21-day-old broilers received MLX granulate (19.24% m/m) via oral gavage at 3.6 mg/kg body weight. Plasma samples were collected over 48 h post administration. MLX concentrations were quantified using validated high-performance liquid chromatography, and pharmacokinetic parameters were estimated using nonlinear mixed-effects modelling (NLME). Mean pharmacokinetic parameters included AUC0–∞ of 79.97 μg·h/mL, Cmax of 14.43 μg/mL, and Tmax of 1 h, indicating rapid absorption and substantial systemic exposure. These findings provide novel insights into MLX disposition from the granulated formulation in broilers and provide pharmacokinetic information to support future investigations evaluating its potential biological effects in poultry production systems.